Cellin Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cellin Technologies is a private, revenue-generating CDMO focused on the high-growth cell therapy and regenerative medicine sector. The company provides essential GMP manufacturing and development services to biotech firms, helping to bridge the gap between research and clinical application. With a validated GMP facility, experienced personnel including a Qualified Person, and a history of handling proprietary technologies like MelCancerVac®, Cellin is positioned as a specialized partner for cell therapy developers in Europe. Its business model is purely service-based, offering flexibility and custom solutions to meet specific client needs.

OncologyRegenerative Medicine

Technology Platform

GMP-compliant cleanroom facility and expertise in aseptic manufacturing, isolation, and expansion of adherent/non-adherent cell lines and primary human cells for cell therapy production.

Opportunities

The booming global cell therapy market drives high demand for specialized GMP manufacturing capacity, particularly from virtual and small biotechs.

Cellin's established EU-compliant facility and expertise position it to capture a share of this growing outsourcing trend, especially for developers targeting the European clinical and commercial markets.

Risk Factors

The company faces intense competition from larger, global CDMOs and risks client concentration.

Its business is highly sensitive to regulatory compliance; any quality failure could result in license suspension and reputational damage.

Technological shifts in cell therapy may also challenge the relevance of its current platform.

Competitive Landscape

Cellin competes in a crowded cell therapy CDMO space against large players (e.g., Lonza, Catalent) and many niche specialists. Its differentiation lies in being a flexible, expert European partner with direct QP support, but it must contend with competitors who have greater scale, broader service offerings, and more global reach.

More companies in Europe - Other →